AstraZeneca says vaccine 76% effective in updated US trial data
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[WaSHINGTON] British-Swedish drugmaker AstraZeneca on Wednesday revised down the efficacy figure for its two-dose Covid vaccine following a clinical trial held across the United States, Peru and Chile.
The company now says its vaccine is 76 per cent effective rather than 79 per cent effective at preventing any kind of symptomatic Covid.
An independent panel of experts appointed to supervise the trial said AstraZeneca failed to include updated data after the company announced the first figure.
AFP
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report
